PepGen Inc.

NASDAQ:PEPG

Biotechnology

Healthcare
$3.83 +5.29%

+$0.09 today

Market cap
$265.27M
Beta
1.93
P/E (TTM)
-1.6
EPS (TTM)
-$1.12
52W Low $1.01High $7.80

Volume 3.39M

Average 1.37M

PEPG Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

PepGen Inc.NASDAQ: PEPG

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow turns negative

Q1 FY2026 investing cash flow was -$1.46M, compared with $17.15M a year earlier. Trailing-twelve-month investing cash flow was -$33.84M. Over 3 fiscal years it compounded at +59.5% a year.

Context

  • Investing cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly investing cash flow holds near -$1.46M or moves back toward the trailing-twelve-month quarterly average of -$8.46M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.46M-97.8% QoQ
Last fiscal yearDec 2025
-$15.24M-59.6% YoY
LTMMar 2026
-$33.84M+266.8% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-108.5%——
1 year-59.6%——
3-year CAGR+59.5%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(15.24M) USD
Year-over-year change
+59.6%

Investing Cash Flow vs competitors

How PEPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +266.8% is the 2nd highest of 8, against a peer median of +145.0%.
  • Over three fiscal years its annual growth of +59.5% compares with a peer median of -67.2%.
PEPG Competitors
Investing Cash Flow for PEPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$191.81M USD+3.9%—1041.5%
FATEFate Therapeutics, Inc.LTM Mar 2026$92.08M USD+145.0%-12.6%1457.9%
NKTXNkarta, Inc.LTM Mar 2026$61.9M USD+164.0%——
MOLNMolecular Partners AGLTM Mar 2026CHF 40.11M CHF-30.7%——
PEPGPepGen Inc.LTM Mar 2026$33.84M USD+266.8%+59.5%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$19.18M USD+449.3%-67.2%3653.9%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$2.69M USD+154.4%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$16K USD-81.6%-71.0%—
Peer median (excluding PEPG) —+145.0%-67.2%1457.9%

Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.28M)(69.1M)(78.63M)(89.98M)(89.66M)
Depreciation & Amortization178K493K850K5.25M5.15M
Deferred Income Tax00000
Stock-Based Compensation1.53M4.76M7.05M11.46M10.61M
Change in Working Capital2.77M4.51M1.95M(5.25M)(6.22M)
Accounts Receivables(4.34M)4.18M26K00
Inventory00000
Accounts Payables2.51M(1.41M)(369K)722K(935K)
Other Working Capital4.61M1.73M2.29M(5.97M)(5.29M)
Other Non-Cash Items196K76K(220K)(3.86M)(1.51M)
Operating Cash Flow(22.6M)(59.27M)(69M)(82.37M)(81.64M)
Capital Expenditures(500K)(3.76M)(2.6M)(497K)(264K)
Acquisitions (Net)00000
Purchases of Investments00(29.4M)(145.17M)(93.97M)
Sales of Investments000108M79M
Other Investing Activities00000
Investing Cash Flow(500K)(3.76M)(32M)(37.67M)(15.24M)
Debt Repayment00000
Common Stock Issued0114.27M086.78M108.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.39M)(2.07M)(189K)1.97M0
Financing Cash Flow147.66M112.19M(189K)88.75M107.98M
Effect of Forex Changes33K(316K)286K(62K)(16K)
Net Change in Cash124.59M48.86M(100.9M)(31.35M)11.09M
Free Cash Flow(23.1M)(63.02M)(71.6M)(82.87M)(81.9M)

PepGen Inc.

NASDAQ:PEPG

Intrinsic Alpha fair value

Locked

Current Price

$3.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.